SG Americas Securities LLC Makes New $133,000 Investment in Alector, Inc. (NASDAQ:ALEC)

SG Americas Securities LLC purchased a new stake in Alector, Inc. (NASDAQ:ALEC) during the fourth quarter, according to its most recent 13F filing with the SEC. The firm purchased 16,726 shares of the company’s stock, valued at approximately $133,000.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Vident Investment Advisory LLC boosted its stake in Alector by 11.6% in the fourth quarter. Vident Investment Advisory LLC now owns 11,440 shares of the company’s stock valued at $106,000 after acquiring an additional 1,188 shares in the last quarter. Diversified Trust Co boosted its position in shares of Alector by 12.3% in the 4th quarter. Diversified Trust Co now owns 14,102 shares of the company’s stock worth $113,000 after purchasing an additional 1,541 shares in the last quarter. Legal & General Group Plc grew its stake in Alector by 3.0% during the 4th quarter. Legal & General Group Plc now owns 53,302 shares of the company’s stock worth $492,000 after buying an additional 1,554 shares during the last quarter. Rhumbline Advisers increased its position in Alector by 2.9% during the 1st quarter. Rhumbline Advisers now owns 61,472 shares of the company’s stock valued at $876,000 after buying an additional 1,753 shares in the last quarter. Finally, Quantbot Technologies LP purchased a new stake in Alector in the first quarter valued at about $25,000. Hedge funds and other institutional investors own 85.83% of the company’s stock.

Wall Street Analyst Weigh In

Separately, HC Wainwright restated a “buy” rating and set a $41.00 price target on shares of Alector in a research note on Wednesday, February 28th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and five have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $14.50.

Insider Buying and Selling

In other Alector news, CEO Arnon Rosenthal sold 18,837 shares of the company’s stock in a transaction on Monday, March 4th. The shares were sold at an average price of $6.92, for a total value of $130,352.04. Following the sale, the chief executive officer now directly owns 2,000,380 shares of the company’s stock, valued at $13,842,629.60. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. In other Alector news, insider Gary Romano sold 6,001 shares of Alector stock in a transaction on Monday, March 4th. The shares were sold at an average price of $6.92, for a total value of $41,526.92. Following the completion of the transaction, the insider now owns 196,313 shares of the company’s stock, valued at $1,358,485.96. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Arnon Rosenthal sold 18,837 shares of the stock in a transaction dated Monday, March 4th. The stock was sold at an average price of $6.92, for a total transaction of $130,352.04. Following the sale, the chief executive officer now directly owns 2,000,380 shares in the company, valued at $13,842,629.60. The disclosure for this sale can be found here. Insiders sold a total of 30,554 shares of company stock valued at $211,434 over the last 90 days. Insiders own 14.00% of the company’s stock.

Alector Stock Down 4.5 %

Shares of NASDAQ:ALEC opened at $5.07 on Thursday. Alector, Inc. has a 52-week low of $3.66 and a 52-week high of $9.06. The stock has a market cap of $485.45 million, a price-to-earnings ratio of -3.27 and a beta of 0.79. The business has a 50-day moving average price of $6.23 and a 200-day moving average price of $6.21.

Alector (NASDAQ:ALEC) last issued its quarterly earnings results on Tuesday, February 27th. The company reported ($0.49) earnings per share for the quarter, topping the consensus estimate of ($0.80) by $0.31. Alector had a negative net margin of 134.34% and a negative return on equity of 77.15%. The company had revenue of $15.19 million for the quarter, compared to the consensus estimate of $8.35 million. As a group, equities analysts anticipate that Alector, Inc. will post -1.85 EPS for the current fiscal year.

Alector Profile

Alector, Inc, a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, an immune activity in the brain with genetic links to multiple neurodegenerative disorders, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases.